Document Type


Publication Date



COVID-19 has produced more than 176 million infected individuals and almost 3.2 million deaths worldwide. The infection results in a dysregulated systemic inflammation, multi-organ dysfunction, and critical illness. Cells of the central nervous system (CNS) are also affected triggering a dysregulated neuroinflammatory response.

Low doses of glucocorticoids (GCs) orally or intravenously administered has been proved to reduce mortality of moderate and severe COVID-19 patients. However, low doses administered by those routes do not reach therapeutic levels in the CNS. In contrast, if dexamethasone is administered by the intranasal route can result in therapeutic doses in the CNS even at low doses of the GC.

Methods: This is an approved multicentric randomized controlled protocol to compare the effectiveness of low doses of intranasal dexamethasone versus intravenous administered in adult moderate and severe COVID-19 patients. The protocol is conducted in five health institutions in Mexico City. A total of 120 patients will be randomized in two groups (intravenous vs intranasal) at 1:1 ratio, both groups will be treated with these dexamethasone schemes for 10 days. The primary outcome of the study will be clinical improvement, defined as a statistically significant higher reduction in the NEWS-2 score in intranasally versus intravenously dexamethasone treated patients. The second outcome will be the reduction in mortality during hospitalization.

Conclusions: This protocol is currently undertaken to improve the efficacy of the standard therapeutic dexamethasone regimen for moderate and severe COVID-19 patients.

Trial registration: identifier: NCT04513184 Registered November 12, 2020 and was approved by COFEPRIS with identifier DI/20/407/04/36. People are currently being recruited.


This preprint is under consideration at Trials. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal.

Creative Commons License

Creative Commons Attribution 4.0 International License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Publication Title




Academic Level


Mentor/PI Department

Office of Human Genetics



To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.